Anti-PDL1 chimeric switch receptor modified T-cell therapy - Marino Biotechnology

Drug Profile

Anti-PDL1 chimeric switch receptor modified T-cell therapy - Marino Biotechnology

Alternative Names: Anti-PD-L1 CSR T cells - Marino Biotechnology; Anti-PDL1 chimeric antigen receptor T-cell therapy - Marino Biotechnology; Autologous anti- PD-L1 CSR T cells - Marino Biotechnology

Latest Information Update: 21 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Marino Biotechnology
  • Class Antineoplastics; CAR-T cell therapies; T lymphocyte cell therapies
  • Mechanism of Action CD274 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma; Solid tumours

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in Solid tumours (Metastatic disease, Recurrent) in China (IV) (NCT02930967)
  • 01 Jul 2016 Phase-I clinical trials in Glioblastoma (Recurrent, Second-line therapy or greater) in China (IV) (NCT02930967)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top